Standing Up to POTS is making a difference in the POTS community through research. To date, we have awarded $318,684 USD to elite POTS research teams in the United States, Australia, Canada, Germany, and Sweden. Our focus when awarding grants is always toward improving the quality of life for people living with POTS right now through better diagnosis and treatment options.
Dr. Satish R. Raj, MD, MSCI, Department of Cardiac Sciences, Libin Cardiovascular Institute, Cumming School of Medicine, University of Calgary - awarded February 2022
The underlying cause of hyperventilation upon standing in many POTS patients is not well understood. Dr. Raj and his team will seek to manipulate carbon dioxide levels in the blood upon standing to better understand the role that chemoreceptors play in POTS symptomology and to explore potential new treatments for POTS patients.
Dr. Jeffrey Boris, MD LLC, pediatric cardiologist in private practice, and Dr. Bruce Kristal, Brigham and Women's Hospital and Harvard Medical School, USA - awarded February 2021
Their project will take an informatics approach to choosing the right treatment for individual postural orthostatic tachycardia syndrome (POTS) patients based on clinical subgroups. We are really excited about the possibility that data can be used to determine best practices for treating patients with particular clusters of symptoms.
Dr. Dennis Lau, Mary-Claire Seeley, Dr. Celine Gallagher, Dr. Adrian Elliot - Centre for Heart Rhythm Disorders at the University of Adelaide: Royal Adelaide Hospital, Australia - awarded February 2021
The aim is to study POTS in Long COVID syndrome with a comprehensive look at inflammation, neuroendocrine dysfunction, and autoimmunity post-COVID infection. The silver lining in this pandemic is that there are many new POTS patients that can be studied where the trigger of symptom onset is known and can be quantified. Approximately 40% of all POTS patients develop symptoms post infection, so we hope that this research will help a large proportion of current POTS patients.
Dr. Artur Fedorowski, Dr. Daiva Daukantaite, Dr. Viktor Hamrefors, and Dr. Karl Firth - Lund University, Stockholm, Sweden - awarded February 2019
This study will explore sleep patterns in POTS patients in their home environment over the course of 28 days. In addition, a variety of physiological variables will be monitored and recorded in real time 24 hours a day to better determine physiological fluctuations in POTS patients. Results are expected in 2023.
Dr. Heather Edgell - York University, School of Kinesiology and Health Sciences, Toronto, Canada - awarded February 2018
The overall aim of this study is to examine how hormonal changes related to a woman's menstrual cycle affect symptoms of POTS, and whether the time of the month matters in diagnosis POTS for women of childbearing age. Further, a novel therapy for alleviating symptoms will be tested.
PUBLICATION: Nardone, Massimo, Juan Guzman, Paula Jean Harvey, John S. Floras, and Heather Edgell. 2020. "Effect of a neck compression collar on cardiorespiratory and cerebrovascular function in postural orthostatic tachycardia syndrome (POTS)." Journal of Applied Physiology. doi.org/10.1152/japplphysiol.00040.2020
Dr. Andrea Maier, Dr. J.B. Schulz, Dr. Roman Rolke, and Dr. Joacim Weis - University Hospital RWTH Aachen, Germany - awarded February 2018
Many patients with POTS report attention deficits and “brain fog” with problems in their everyday life and work, predominantly in upright posture. Specific symptomatic or medical therapies do not exist. This study will investigate problems of concentration, attention and/or cognitive dysfunction in people with POTS, autoimmune autonomic neuropathy, small fiber neuropathy and Ehlers-Danlos Syndrome compared to healthy controls. Results are expected in 2021.
Dr. Svetlana Blitshteyn - Dysautonomic Clinic, Buffalo, New York, USA - awarded June 2017
This study examines the connection between Lyme Disease and POTS, a particularly important issue for our friends in the Northeastern United States and other places where Lyme disease is prevalent. Results are expected in 2020.